China’s early stage Panacea

How Panacea plans to deploy funds to back early stage biotech, medtech in China

Despite a recent wave of large funds investing in Chinese biotechs, new Chinese VC Panacea Venture believes a pair of funds totaling roughly $300 million is more than enough to pursue its early stage investing and company formation strategy in Chinese life

Read the full 422 word article

How to gain access

Continue reading with a
two-week free trial.